[Plasmin-mediated activation of the coagulation system. A study of patients with acute ischemic heart disease treated with recombinant tissue-plasminogen activator].
We have studied the response of haemostatic reaction products in peripheral blood of patients with acute ischaemic heart disease receiving combined recombinant tissue type plasminogen activator/heparin therapy. We have found evidence that formation of excessive amounts of plasmin in vivo in relation to such therapy significantly enhances the degradation of fibrin, and of fibrinogen as well as the formation of thrombin. We conclude that excessive plasmin formation by thrombolytic therapy causes systemic effects including activation of coagulation.
Gram
J B
JB
Kliniskkemisk afdeling, Centralsygehuset i Esbjerg.
Munkvad
S
S
Leebeek
F W
FW
Kluft
C
C
Jespersen
J
J
D000208:Acute Disease; D001777:Blood Coagulation / Q000187:drug effects*; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005341:Fibrinolysin / Q000096:biosynthesis; D006801:Humans; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D005338:Fibrin Fibrinogen Degradation Products; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin
Plasminmedieret aktivering af koagulationssystemet. En undersøgelse af patienter med akut iskoemisk hjertesygdom behandlet med rekombinant voevsplasminogenaktivator.